{"nct_id":"NCT03697824","title":"Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a","status":"WITHDRAWN","status_verified_date":"2019-10","start_date":"2019-02-25","start_date_type":"ESTIMATED","primary_completion_date":"2022-07-18","primary_completion_date_type":"ESTIMATED","completion_date":"2022-07-18","completion_date_type":"ESTIMATED","phases":["PHASE2"],"tickers":["GSK"]}